دورية أكاديمية
[The German COVID-19 rheumatism register].
| العنوان: | [The German COVID-19 rheumatism register]. |
|---|---|
| عنوان ترانسليتريتد: | Das deutsche COVID-19-Rheumaregister. |
| المؤلفون: | Hasseli R; Medizinische Klinik D, Sektion für Rheumatologie und Klinische Immunologie, Abteilung für Translationale Rheumatologie und Immunologie, Institut für Muskuloskelettale Medizin (IMM), Universitätsklinikum Münster, Münster, Deutschland. hasseli@rheumathek.de.; Abteilung für Rheumatologie und Klinische Immunologie, Justus-Liebig-Universität Gießen, Campus Kerckhoff, Bad Nauheim, Deutschland. hasseli@rheumathek.de., Regierer AC; Programmbereich Epidemiologie und Versorgungsforschung, Deutsches Rheuma-Forschungszentrum, Berlin, Deutschland., Strangfeld A; Programmbereich Epidemiologie und Versorgungsforschung, Deutsches Rheuma-Forschungszentrum, Berlin, Deutschland., Pfeil A; Funktionsbereich Rheumatologie und Osteologie, Klinik für Innere Medizin III, Universitätsklinikum Jena, Jena, Deutschland. |
| مؤلفون مشاركون: | die COVID-19-Register Kommission der Deutschen Gesellschaft für Rheumatologie |
| المصدر: | Zeitschrift fur Rheumatologie [Z Rheumatol] 2024 May 30. Date of Electronic Publication: 2024 May 30. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | English Abstract; Journal Article; Review |
| اللغة: | German |
| بيانات الدورية: | Publisher: Springer Country of Publication: Germany NLM ID: 0414162 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1435-1250 (Electronic) Linking ISSN: 03401855 NLM ISO Abbreviation: Z Rheumatol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2006- : Heidelberg : Springer Original Publication: Darmstadt, Steinkopff. |
| مستخلص: | At the beginning of the coronavirus disease 2019 (COVID-19) pandemic in December 2019 there was no available evidence regarding the management of immunosuppressive or immunomodulatory treatment and the potential outcomes of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infections in inflammatory rheumatic diseases (IRD). As a result, the Justus Liebig University of Giessen, Germany, in collaboration with the German Society for Rheumatology, established the German COVID-19 register ( www.covid19-rheuma.de ). The COVID-19 register enabled for the first time a systematic documentation and evaluation of viral infections in patients with IRD. The data collection started as early as March 2020. Currently, the register is one of the largest global registers in the field of COVID-19 and IRD. As of 18 December 2023 the register has recorded more than 7100 cases. The first scientific findings on SARS-CoV‑2 infections in IRD patients were generated from the register in 2020, showing an association between disease activity of IRD, certain comorbidities, such as cardiovascular diseases and treatment with rituximab, with an unfavorable course. The contents and construction of the database of the register were designed at the conception to allow collaboration and data exchange with other national and international registers (e.g., EULAR COVID-19 register, COVID-19 global rheumatology alliance and the Lean European open survey on SARS-CoV‑2 infected patients). In addition, other registers and surveys were initiated. A vaccination register documents the tolerability and possible adverse reactions to COVID-19 vaccination in IRD patients. The data resulted in numerous publications and formed the basis for national and international recommendations for action in the care and vaccination of IRD patients during the COVID-19 pandemic. In summary, the German COVID-19 register has made a significant contribution to the understanding of the course of COVID-19 in IRD patients and has facilitated international collaboration for a better understanding of COVID-19 and IRD. (© 2024. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.) |
| References: | Hasseli R, Pfeil A, Hoyer BF et al (2021) German registry www.Covid19-Rheuma.de : Status report after 1 year of the pandemic. Z Rheumatol 80:641–646. https://doi.org/10.1007/s00393-021-01034-y. (PMID: 10.1007/s00393-021-01034-y341967938246125) Hasseli R, Mueller-Ladner U, Schmeiser T et al (2020) National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV‑2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV‑2 infections in patients with IRD. Rmd Open 6:e1332. https://doi.org/10.1136/rmdopen-2020-001332. (PMID: 10.1136/rmdopen-2020-001332328789947507994) Hasseli R, Mueller-Ladner U, Hoyer BF et al (2021) Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open 7:e1464. https://doi.org/10.1136/rmdopen-2020-001464. (PMID: 10.1136/rmdopen-2020-00146433479021) Regierer AC, Hasseli R, Schäfer M et al (2021) TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV‑2 infection in patients with RMD. Rmd Open 7:e1896. https://doi.org/10.1136/rmdopen-2021-001896. (PMID: 10.1136/rmdopen-2021-00189634670840) Schulze-Koops H, Iking-Konert C, Leipe J et al (2020) Recommendations of the German Society for Rheumatology for management of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic—Update July. Z Rheumatol 2020(79):679–685. https://doi.org/10.1007/s00393-020-00851-x. (PMID: 10.1007/s00393-020-00851-x) Schulze-Koops H, Krüger K, Hoyer BF et al (2021) Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in times of SARS-CoV-2-methodology, key messages and justifying information. Rheumatol Oxf Engl 60:2128–2133. https://doi.org/10.1093/rheumatology/keab072. (PMID: 10.1093/rheumatology/keab072) Izadi Z, Gianfrancesco MA, Schmajuk G et al (2022) Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study. Lancet Rheumatol 4:e603–e613. https://doi.org/10.1016/S2665-9913(22)00192-8. (PMID: 10.1016/S2665-9913(22)00192-8359094419313519) Izadi Z, Gianfrancesco MA, Aguirre A et al (2022) Development of a prediction model for COVID-19 acute respiratory distress syndrome in patients with rheumatic diseases: results from the global rheumatology alliance. Regist ACR Open Rheumatol 4:872–882. https://doi.org/10.1002/acr2.11481. (PMID: 10.1002/acr2.11481) Izadi Z, Brenner EJ, Mahil SK et al (2021) Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19. JAMA Netw Open 4:e2129639. https://doi.org/10.1001/jamanetworkopen.2021.29639. (PMID: 10.1001/jamanetworkopen.2021.29639346616638524310) Sattui SE, Conway R, Putman MS et al (2021) Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. Lancet Rheumatol 3:e855–e864. https://doi.org/10.1016/S2665-9913(21)00316-7. (PMID: 10.1016/S2665-9913(21)00316-7347788438570701) Ugarte-Gil MF, Alarcón GS, Izadi Z et al (2022) Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. Ann Rheum Dis 81:970–978. https://doi.org/10.1136/annrheumdis-2021-221636. (PMID: 10.1136/annrheumdis-2021-22163635172961) Yeoh S‑A, Gianfrancesco M, Lawson-Tovey S et al (2022) Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. RMD Open 8:e2508. https://doi.org/10.1136/rmdopen-2022-002508. (PMID: 10.1136/rmdopen-2022-00250836100295) Hasseli R, Hanses F, Stecher M et al (2023) No Increased Lethality in Covid-19 in Patients with Inflammatory Rheumatic Diseases Compared to the General Population—a Comparison of Two German Registries. (PMID: 10.3389/fmed.2024.1332716) https://www.eular.org/web/static/lib/pdfjs/web/viewer.html ?. Zugegriffen: 9. Jan. 2024. Data from the Provider-Entered Registries. https://rheum-covid.org/map/ ;. Zugegriffen: 9. Jan. 2024. Strangfeld A, Schäfer M, Gianfrancesco MA et al (2021) Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 80:930–942. https://doi.org/10.1136/annrheumdis-2020-219498. (PMID: 10.1136/annrheumdis-2020-21949833504483) Hasseli R, Pfeil A, Krause A et al (2021) A survey to evaluate knowledge, perceptions and attitudes toward COVID-19 vaccinations among rheumatologists in Germany. Rheumatol Int 41:1949–1956. https://doi.org/10.1007/s00296-021-04986-1. (PMID: 10.1007/s00296-021-04986-1344981128425463) Abstract Archive EULAR http://scientific.sparx-ip.net/archiveeular/index.cfm?c=a&searchfor=hasseli&view=1&item=2021POS1261 ;. Zugegriffen: 9. Jan. 2024. Hasseli R, Bimba Hoyer FH-ML, Bimba Hoyer FH-ML et al (2022) Verträglichkeit und Sicherheit von COVID-19-Impfstoffen nach Erstimpfung bei Patienten mit rheumatischen Erkrankungen45. Kongr Dtsch Ges Rheumatol (dgrh) 45 Kongr Dtsch Ges Rheumatol 18:69–72. Specker C, Ad-hoc-Kommission COVID-19 der DGRh, Schulze-Koops H et al (2021) Vaccination against SARS-CoV‑2 in inflammatory rheumatic diseases : Recommendations of the German Society for Rheumatology for physicians and patients. Z Rheumatol 80:43–44. https://doi.org/10.1007/s00393-020-00955-4. (PMID: 10.1007/s00393-020-00955-4334380617802998) Schulze-Koops H, Krueger K, Vallbracht I et al (2021) Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab. Ann Rheum Dis 80:e67. https://doi.org/10.1136/annrheumdis-2020-218075. (PMID: 10.1136/annrheumdis-2020-21807532591357) Hasseli R, Pfeil A, Hoyer BF et al (2021) Do patients with rheumatoid arthritis show a different course of COVID-19 compared to patients with spondyloarthritis? Clin Exp Rheumatol 39:639–647. https://doi.org/10.55563/clinexprheumatol/1bq5pl. (PMID: 10.55563/clinexprheumatol/1bq5pl33822706) Hasseli R, Richter JG, Hoyer BF et al (2023) Characteristics and outcomes of SARS-CoV‑2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases. Rmd Open 9:e2998. https://doi.org/10.1136/rmdopen-2023-002998. (PMID: 10.1136/rmdopen-2023-00299837068915) |
| فهرسة مساهمة: | Keywords: Immune‐mediated inflammatory diseases; Immunomodulatory therapy; Immunosuppressive therapy; SARS-CoV‑2; Vaccination Local Abstract: [Publisher, German] Zu Beginn der COVID-19(Coronavirus-Erkrankung 2019)-Pandemie im Dezember 2019 gab es keine Evidenz zur Steuerung der immunsuppressiven oder immunmodulatorischen Therapie oder zum Outcome einer SARS-CoV-2(„severe acute respiratory syndrome coronavirus type 2“)-Infektion bei entzündlich-rheumatischen Erkrankungen (ERE). Die Justus-Liebig-Universität Gießen hat in Zusammenarbeit mit der Deutschen Gesellschaft für Rheumatologie das Deutsche COVID-19-Register ( www.covid19-rheuma.de ) etabliert. Durch das COVID-19-Register wurden erstmals eine systematische Erfassung und Auswertung einer viralen Infektion bei Patienten mit ERE durchgeführt. Die Datenerfassung begann bereits im März 2020. Das Register zählt mittlerweile zu den größten weltweit auf diesem Gebiet. Bis zum 18.12.2023 wurden über 7100 Fälle erfasst. Im Jahr 2020 wurden erste wissenschaftliche Erkenntnisse zur SARS-CoV-2-Infektion bei ERE-Patienten aus dem Register generiert. Diese zeigten eine Assoziation zwischen der Krankheitsaktivität der ERE, bestimmten Komorbiditäten wie kardiovaskulären Erkrankungen und Therapien wie Rituximab mit einem ungünstigen Verlauf. Die Inhalte und der Aufbau der Datenbank wurden bereits bei der Konzeption so gestaltet, dass Kooperationen und Datentransfers mit anderen nationalen und internationalen Kooperationen (z. B. EULAR-COVID-19-Registry, COVID-19-Global Rheumatology Alliance sowie Lean European Open Survey on SARS-CoV-2-infizierten Patienten) möglich sind. Zusätzlich wurden weitere Register und Umfragen initiiert. Ein Impfregister erfasste die Verträglichkeit und möglichen Nebenwirkungen der COVID-19-Impfung bei ERE-Patienten. Die Daten führten zu zahlreichen Publikationen und bildeten die Grundlage für nationale und internationale Handlungsempfehlungen zur Betreuung und Impfung von ERE-Patienten während der COVID-19-Pandemie. Zusammenfassend hat das Deutsche COVID-19-Register einen wesentlichen Beitrag zur Erforschung des Verlaufs von COVID-19 bei ERE-Patienten geleistet und eine internationale Zusammenarbeit ermöglicht, um ein besseres Verständnis von COVID-19 und ERE zu erlangen. |
| تواريخ الأحداث: | Date Created: 20240530 Latest Revision: 20240530 |
| رمز التحديث: | 20240531 |
| DOI: | 10.1007/s00393-024-01516-9 |
| PMID: | 38816582 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1435-1250 |
|---|---|
| DOI: | 10.1007/s00393-024-01516-9 |